Attached files
file | filename |
---|---|
10-K - 10-K - Neoleukin Therapeutics, Inc. | d124615d10k.htm |
EX-31.2 - EX-31.2 - Neoleukin Therapeutics, Inc. | d124615dex312.htm |
EX-10.6 - EX-10.6 - Neoleukin Therapeutics, Inc. | d124615dex106.htm |
EX-32.2 - EX-32.2 - Neoleukin Therapeutics, Inc. | d124615dex322.htm |
EX-32.1 - EX-32.1 - Neoleukin Therapeutics, Inc. | d124615dex321.htm |
EX-10.7 - EX-10.7 - Neoleukin Therapeutics, Inc. | d124615dex107.htm |
EX-31.1 - EX-31.1 - Neoleukin Therapeutics, Inc. | d124615dex311.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statements Nos.333-194490 and 333-203179 on Form S-8 and Nos. 333-203180 and 333-208651 on Form S-3 of our report dated March 14, 2016, relating to the consolidated financial statements of Aquinox Pharmaceuticals, Inc. appearing in this Annual Report on Form 10-K of Aquinox Pharmaceuticals, Inc. for the year ended December 31, 2015.
/s/ Deloitte LLP
Chartered Professional Accountants
Vancouver, Canada
March 14, 2016